97 related articles for article (PubMed ID: 2801726)
21. Catabolism and distribution of functionally heterogeneous human antithrombin III.
Marciniak E; Romond EH
J Lab Clin Med; 1987 Jan; 109(1):89-96. PubMed ID: 3794520
[TBL] [Abstract][Full Text] [Related]
22. A pasteurized antithrombin III concentrate for clinical use.
Smith JK; Winkelman L; Evans DR; Haddon ME; Sims G
Vox Sang; 1985; 48(6):325-32. PubMed ID: 4013136
[TBL] [Abstract][Full Text] [Related]
23. A novel matrix for high performance affinity chromatography and its application in the purification of antithrombin III.
Zhao R; Luo J; Shangguan D; Liu G
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):175-81. PubMed ID: 15664348
[TBL] [Abstract][Full Text] [Related]
24. [Perioperative management for transurethral resection of bladder tumor (TUR-Bt) associated with congenital antithrombin III deficiency].
Mizuno J; Kato S; Namai S; Komiya Y; Kuwana Y; Morita S
Masui; 2009 Dec; 58(12):1524-7. PubMed ID: 20055199
[TBL] [Abstract][Full Text] [Related]
25. Membrane chromatography for rapid purification of recombinant antithrombin III and monoclonal antibodies from cell culture supernatant.
Lütkemeyer D; Bretschneider M; Büntemeyer H; Lehmann J
J Chromatogr; 1993 Jun; 639(1):57-66. PubMed ID: 8331144
[TBL] [Abstract][Full Text] [Related]
26. New process for purifying high purity α1-antitrypsin from Cohn Fraction IV by chromatography: A promising method for the better utilization of plasma.
Huangfu C; Zhang J; Ma Y; Jia J; Lv M; Zhao X; Zhang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1046():156-164. PubMed ID: 28183045
[TBL] [Abstract][Full Text] [Related]
27. [Antithrombin III. Physiologic, physiopathologic and laboratory aspects].
de Sousa JC; Ferreira R; Carriço F; Nunes V; Geraldes MJ; Parreira F; Ribeiro C
Rev Port Cardiol; 1991 Sep; 10(9):693-9. PubMed ID: 1747261
[TBL] [Abstract][Full Text] [Related]
28. An improved method for removal of antithrombin III from post-heparin plasma lipase fractions with a high recovery rate.
Moriguchi EH; Tamachi H; Homma Y; Goto Y
Tokai J Exp Clin Med; 1991 Mar; 16(1):33-41. PubMed ID: 1780907
[TBL] [Abstract][Full Text] [Related]
29. Three novel high performance affinity chromatographic media for the separation of antithrombin III from human plasma.
Zhao Y; Zhao R; Shangguan D; Xiong S; Liu G
Biomed Chromatogr; 2001 Dec; 15(8):487-92. PubMed ID: 11748680
[TBL] [Abstract][Full Text] [Related]
30. Interaction between human tissue thromboplastin and human antithrombin III.
Hirahara K; Matsuishi T; Suzuki N; Kurata M
Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):2984-7. PubMed ID: 2632043
[TBL] [Abstract][Full Text] [Related]
31. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
Takahashi HK; Nader HB; Dietrich CP
Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
[TBL] [Abstract][Full Text] [Related]
32. Purification and characterization of guinea pig antithrombin III.
Clement LT
Prep Biochem; 1983; 13(1):1-20. PubMed ID: 6856582
[TBL] [Abstract][Full Text] [Related]
33. Heparin binding domain of antithrombin III: characterization using a synthetic peptide directed polyclonal antibody.
Smith JW; Dey N; Knauer DJ
Biochemistry; 1990 Sep; 29(38):8950-7. PubMed ID: 2271570
[TBL] [Abstract][Full Text] [Related]
34. Interaction of antithrombin III with surface-immobilized albumin-heparin conjugates.
van Delden CJ; Engbers GH; Feijen J
J Biomed Mater Res; 1995 Nov; 29(11):1317-29. PubMed ID: 8582900
[TBL] [Abstract][Full Text] [Related]
35. Characterization of antithrombin III from human plasma by two-dimensional gel electrophoresis and capillary electrophoretic methods.
Kremser L; Brückner A; Heger A; Grunert T; Buchacher A; Josic D; Allmaier G; Rizzi A
Electrophoresis; 2003 Dec; 24(24):4282-90. PubMed ID: 14679575
[TBL] [Abstract][Full Text] [Related]
36. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity.
Picard V; Ersdal-Badju E; Bock SC
Biochemistry; 1995 Jul; 34(26):8433-40. PubMed ID: 7599134
[TBL] [Abstract][Full Text] [Related]
37. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life.
Byrnes JW; Swearingen CJ; Prodhan P; Fiser R; Dyamenahalli U
ASAIO J; 2014; 60(1):57-62. PubMed ID: 24296776
[TBL] [Abstract][Full Text] [Related]
38. Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III.
Hoffman C; Hultin MB
Thromb Res; 1986 Jul; 43(2):143-51. PubMed ID: 3738857
[TBL] [Abstract][Full Text] [Related]
39. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
[TBL] [Abstract][Full Text] [Related]
40. [Purification of antithrombin III by affinity chromatography in heparin-Trisacryl].
Allary M; Boschetti E; Majurel M; Girot P; Saint-Blancard J
Ann Pharm Fr; 1986; 44(5):379-86. PubMed ID: 3579161
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
